Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Good

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Clinical Pharmacology and Therapeutics|December 1, 1979
Acyclovir kinetics after intravenous infusionP de Miranda, R J Whitley, M R Blum, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1997
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activityS M Daluge, S S Good, M B Faletto, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 10, 2020
Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell CancerK J Harrington, S A Bhide, M D Forster, et al.
European Heart Journal|December 8, 2025
Fractional flow reserve vs angiography in non-ST- elevation myocardial infarction: long-term results of the FAMOUS-NSTEMI trialColin Berry, Bethany Stanley, Patrycja Duklas, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of actionKaren K Biron, Robert J Harvey, Stanley C Chamberlain, et al.
Technical Innovations & Patient Support in Radiation Oncology|August 18, 2025
Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical careElena Moreno-Olmedo, Kasia Owczarczyk, Eliot Chadwick, et al.
Nursing Outlook|September 13, 2024
Call to action: Blueprint for change in acute and critical care nursingMartha A Q Curley, Margarete L Zalon, Maureen A Seckel, et al.
Nature Communications|February 3, 2022
A dual mechanism of action of AT-527 against SARS-CoV-2 polymeraseAshleigh Shannon, Véronique Fattorini, Bhawna Sama, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 11, 2022
UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative RadiotherapyP Diez, G G Hanna, K L Aitken, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|December 1, 1979
Acyclovir kinetics after intravenous infusionP de Miranda, R J Whitley, M R Blum, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1997
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activityS M Daluge, S S Good, M B Faletto, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|June 10, 2020
Looking a Gift Horse in the Mouth: Observations on NHS England's Interim Guidance on Pembrolizumab in Head and Neck Squamous Cell CancerK J Harrington, S A Bhide, M D Forster, et al.
European Heart Journal|December 8, 2025
Fractional flow reserve vs angiography in non-ST- elevation myocardial infarction: long-term results of the FAMOUS-NSTEMI trialColin Berry, Bethany Stanley, Patrycja Duklas, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of actionKaren K Biron, Robert J Harvey, Stanley C Chamberlain, et al.
Technical Innovations & Patient Support in Radiation Oncology|August 18, 2025
Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical careElena Moreno-Olmedo, Kasia Owczarczyk, Eliot Chadwick, et al.
Nursing Outlook|September 13, 2024
Call to action: Blueprint for change in acute and critical care nursingMartha A Q Curley, Margarete L Zalon, Maureen A Seckel, et al.
Nature Communications|February 3, 2022
A dual mechanism of action of AT-527 against SARS-CoV-2 polymeraseAshleigh Shannon, Véronique Fattorini, Bhawna Sama, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 11, 2022
UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative RadiotherapyP Diez, G G Hanna, K L Aitken, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
Pageof 11